AI Model Accurately Detects Cardiac Amyloidosis on Echocardiograms
July 9, 2025
An AI tool using echocardiograms accurately screens for cardiac amyloidosis, outperforming traditional detection methods.
Key Details
- AI model analyzes echocardiogram (ultrasound) images to screen for cardiac amyloidosis.
- Developed by Mayo Clinic and Ultromics; validated in a global, multi-ethnic cohort across 18 hospitals.
- Achieved 85% sensitivity and 93% specificity in detecting or ruling out cardiac amyloidosis.
- Outperformed existing clinical scoring systems for early diagnosis.
- FDA-cleared and already being implemented in multiple US hospitals.
Why It Matters
Early, accurate identification of cardiac amyloidosis is critical due to effective therapies available only at earlier disease stages. AI-based screening of routine cardiac ultrasound could substantially improve detection rates and patient outcomes, supporting broader integration of imaging AI in clinical care.